Erik H.C.J. Buster - Concepedia

Author

Erik H.C.J. Buster

Also Known As

Buster, Erik H., E BUSTER, E Buster, E H C J Buster, E. Buster, E. H. C. J. Buster, E.H.C.J. Buster, Erik H C J Buster, Erik H. C. J. Buster, Erik H.C.J. Buster

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Goethe University Frankfurt Istanbul University

About

Erik H.C.J. Buster is an author at Erasmus MC specializing in medicine, hepatitis, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	985
2	Hepatology	3	3	574
3	Immunology	3	3	950
4	Emergency Medicine	1	1	17
5	Pathology	1	1	18

Erik H.C.J. Buster

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b Erik H.C.J. Buster, Hajo J. Flink, Yılmaz Çakaloğlu, Gastroenterology Autoimmune DiseaseHbsag LossPeginterferon α-2BImmunologyHepatitis	2008	394
Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa Erik H.C.J. Buster, Bettina E. Hansen, George Lau, Gastroenterology Hepatic DisordersAutoimmune DiseaseHepatologyViral HepatitisImmunology	2009	391
Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B Milan J. Sonneveld, Vincent Wai‐Sun Wong, Andrea M. Woltman, Gastroenterology HepatologyAutoimmune DiseasePolymorphisms Near Il28bViral HepatitisImmunology	2011	165
Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis† ‡ § Erik H.C.J. Buster, Bettina E. Hansen, Jean Delwaide, Hepatology	2007	115
Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Erik H.C.J. Buster, Karel J. van Erpecum, Solko W. Schalm, PubMed	2008	58
Prediction of the response to peg‐interferon‐alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment Bettina E. Hansen, Erik H.C.J. Buster, Ewout W. Steyerberg, Journal of Medical Virology	2010	42
Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients Erik H.C.J. Buster, Hajo J. Flink, Halis Şimşek, The American Journal of Gastroenterology	2009	35
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? Erik H.C.J. Buster, Harry L.A. Janssen PubMed	2006	31
Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine Erik H.C.J. Buster, Hanneke J. van Vuuren, Pieter E. Zondervan, European Journal of Gastroenterology & Hepatology PathologyLiver BiopsyNodular Regenerative HyperplasiaCirrhosisAutoimmune Liver Disease	2008	18
Implementation of a regional video multidisciplinary team meeting is associated with an improved prognosis for patients with oesophageal cancer A mixed methods approach Josianne C.H.B.M. Luijten, Vera C. Haagsman, Misha Luyer, European Journal of Surgical Oncology Palliative CareEsophageal CancerImproved PrognosisMedicineCancer Management	2021	17

Page 1